Key features
Investment approach geared towards long-term structural growth opportunities – focus on companies versus countries
Emphasis on companies with franchise sustainability and attractive valuations
Dedicated emerging markets team has managed the Series since 2006
Daily pricing
as of
11/22/2024
NAV 1-day net change
0.38
Total net assets
as of
10/31/2024
All share classes
$622.9 million
Overview
Series identifiers |
CUSIP |
246493878 |
Benchmark
Portfolio
Market cap (median) Source: FactSet
$6.6 billion
Market cap (weighted average) Source: FactSet
$209.3 billion
Portfolio turnover (last fiscal year)
4%
International equities & depositary receipts
100.9%
Cash, cash equivalents and other assets
-1.0%
Values in excess of 100% and negative values may appear as the result of certain assets and liabilities. See the Series' prospectus for securities in which the Series would typically invest.
Top 10 holdings
as of 10/31/2024
Holdings are as of the date indicated and subject to change.
List may exclude cash and cash equivalents. Please see the Series' complete list of holdings for more information.
Holdings based by issuer.
TAIWAN SEMICONDUCTOR MANUFACTURING CO LT
18.66
RELIANCE INDUSTRIES LTD
8.79
SAMSUNG ELECTRONICS CO LTD
7.34
ALIBABA GROUP HOLDING LTD
4.15
TENCENT HOLDINGS LTD
2.73
Total % Portfolio in Top 10 holdings - 65.83%
Management
Liu-Er Chen, CFA
-
Managing Director, Head of Emerging Markets Equity
-
Start date on the Fund:
September 2006
-
Years of industry experience:
29
-
Read bio
Liu-Er Chen
Managing Director, Head of Emerging Markets Equity
- Joined Delaware Investments in 2006, acquired by Macquarie in 2010
- Based in Boston
Liu-Er is Head of Emerging Markets Equity at Macquarie Asset Management (MAM), responsible for managing for the firm’s emerging markets equity portfolios and Delaware Healthcare Fund, a role he first assumed with Delaware Investments in September 2007.
Before joining Delaware Investments, Liu-Er worked at Evergreen Investment Management Company for nearly 11 years, where he was the sole manager of the Evergreen Health Care and Emerging Markets funds. Prior to his career in asset management, Liu-Er worked in sales, marketing, and business development for major American and European pharmaceutical and medical device companies.
Liu-Er earned a Master of Business Administration from Columbia Business School and holds the Chartered Financial Analyst® designation.
Fees
The following table describes the fees and expenses that you may pay if you buy, hold,
and sell shares of the Series. The fee table does not reflect any fees or sales charges
imposed by variable insurance contracts. If it did, the expenses would be higher.
Annual portfolio operating expenses |
Management fees |
1.24% |
Distribution and service (12b-1) fees |
none |
Other expenses |
0.06% |
Total annual series operating expenses |
1.30% |
Fee waivers and expense reimbursements1 |
(0.12%) |
Total annual series operating expenses after fee waivers and expense reimbursements |
1.18% |
Please see the prospectus and SAI for additional information.
1Net expense ratio reflects a contractual waiver of certain fees and/or expense
reimbursements from May 1, 2024 through April 30, 2025. Please see the fee table in the Series'
prospectus for more information.
Resources
Shareholder report – Annual
Shareholder report – Semi-annual